LOS ANGELES CAPITAL MANAGEMENT LLC added 304,281 shares of AbbVie, worth $61.96 million, increasing their post-trade stake to 2,324,286 shares valued at $538.17 million as of September 30, 2025. AbbVie now accounts for 2.01% of their U.S. equity assets, moving it outside the top five holdings in the fund’s portfolio.

AbbVie’s shares were priced at $232.06 as of October 20, 2025, showing a 24.4% increase over the past year. The company’s revenue for the trailing twelve months stood at $58.33 billion, with a net income of $3.77 billion and a dividend yield of 2.83%. AbbVie operates as a leading global biopharmaceutical company, offering a portfolio of pharmaceutical products targeting various markets.

Investors are showing confidence in AbbVie’s growth potential, with the company balancing resilience and innovation. AbbVie’s evolving portfolio, including newer drugs like Rinvoq with exclusivity until 2037, reflects a strategy focused on long-term value. With shares up 24% year to date, AbbVie’s consistent execution demonstrates its ability to deliver results in an evolving market.

Read more at Nasdaq: AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth